453 results on '"Julian, Thomas B"'
Search Results
102. Obstruction of the pancreatic duct by a granular cell tumor
103. NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.
104. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.
105. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
106. Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer
107. Abstract OT1-3-02: Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 af
108. Abstract PD6-3: Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer
109. Abstract P5-21-01: Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials
110. Boost Radiotherapy for the Treatment of Ductal Carcinoma In Situ Remains Controversial
111. Landmark Clinical Trials Influencing Surgical Management of Non-invasive and Invasive Breast Cancer
112. NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC.
113. Are Margins Bigger Than “No Ink on Tumor” Better? Decidedly Not!
114. Ductal carcinomain situ: an overview
115. 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.
116. NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx).
117. Is excision alone adequate for low-risk DCIS of the breast treated with breast conserving therapy
118. Long-Term Followup of Intracavitary Balloon Catheter Retreatment Irradiation of the Breast
119. Ductal Carcinoma In Situ of the Breast.
120. Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28
121. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
122. Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.
123. Relationship Between Arm Morbidity and Patient-Reported Outcomes Following Surgery in Women with Node-Negative Breast Cancer: NSABP Protocol B-32
124. Accelerated Partial-Breast Irradiation: Trial by Media or by Science?
125. NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).
126. A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43.
127. Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
128. Mature follow-up of Low-dose rate interstitial brachytherapy following ipsilateral breast tumor recurrence in patients initially treated with breast conservation therapy
129. Select patients carefully for regional nodal irradiation
130. Breast conservation surgery and radiation for a patient with synchronous primary breast cancers and BRCA1/BRCA2 positivity: is mastectomy required?
131. Prophylactic and Therapeutic Breast Conservation inBRCA1/2Mutation Carriers
132. Axillary Recurrences Following Positive Sentinel Lymph Node Biopsy with Individual Tumor Cells or Micrometastases and No Axillary Dissection1
133. The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes
134. Patient-Reported Outcomes in Sentinel Node–Negative Adjuvant Breast Cancer Patients Receiving Sentinel-Node Biopsy or Axillary Dissection: National Surgical Adjuvant Breast and Bowel Project Phase III Protocol B-32
135. Response to “Unacceptable Cosmesis in a Protocol Investigating Intensity-Modulated Radiotherapy With Active Breathing Control for Accelerated Partial-Breast Irradiation” (Int J Radiat Oncol Biol Phys 2010;76:71–78) and “Toxicity of Three-Dimensional Conformal Radiotherapy for Accelerated Partial Breast Irradiation” Int J Radiat Oncol Biol Phys 2009;75:1290–1296)
136. Consistent Reductions in Skin Doses Using the Contura™ Multi-Lumen Balloon Breast Brachytherapy Catheter to Deliver Accelerated Partial Breast Irradiation
137. In Reply to Dr. Beal et al
138. If Sentinel Node Micrometastases Are the Question, Are Clinical Trials the Answer?
139. Accelerated Partial Breast Irradiation Consensus Statement from the American Society for Radiation Oncology (ASTRO)
140. Long-term Cosmesis After Lumpectomy and Brachytherapy in the Management of Carcinoma of the Previously Irradiated Breast
141. Initial dosimetric experience: Contura ™ Multilumen Balloon Registry Trial
142. Completion of axillary dissection for a positive sentinel node: Necessary or not?
143. The Half Century of Clinical Trials of the National Surgical Adjuvant Breast and Bowel Project
144. Update on the NSABP B-39/RTOG 0413 Clinical Trial
145. Ductal Carcinoma In Situ: Biology, Diagnosis, and New Therapies
146. Compliance With Patient-Reported Outcomes in Multicenter Clinical Trials: Methodologic and Practical Approaches
147. MRI Evaluation of the Contralateral Breast in Women With Recently Diagnosed Breast Cancer
148. Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS?
149. Safety Profile of Amnion-Derived Cellular Cytokine Solution (ACCS) Following Topical Skin Application in Patients Receiving Breast Radiotherapy.
150. Partial Breast Irradiation: Continuing the Retreat from Halstedian Breast Cancer Management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.